Sun Pharmaceuticals Industries Ltd
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]
- Market Cap ₹ 3,88,824 Cr.
- Current Price ₹ 1,621
- High / Low ₹ 1,634 / 922
- Stock P/E 94.4
- Book Value ₹ 100
- Dividend Yield 0.71 %
- ROCE 16.8 %
- ROE 13.9 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 16.2 times its book value
- Company has a low return on equity of 3.87% over last 3 years.
- Working capital days have increased from 71.6 days to 131 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,016 | 2,432 | 2,829 | 8,028 | 7,719 | 7,684 | 8,982 | 10,303 | 12,532 | 14,116 | 15,586 | 20,812 | 20,584 | |
2,253 | 1,919 | 2,810 | 8,581 | 8,130 | 7,559 | 7,998 | 8,513 | 9,815 | 11,849 | 12,917 | 14,389 | 14,530 | |
Operating Profit | 1,762 | 513 | 19 | -552 | -410 | 125 | 985 | 1,790 | 2,717 | 2,267 | 2,669 | 6,423 | 6,055 |
OPM % | 44% | 21% | 1% | -7% | -5% | 2% | 11% | 17% | 22% | 16% | 17% | 31% | 29% |
40 | 236 | -2,700 | 205 | 367 | 504 | 171 | 23 | 1,506 | 93 | -624 | -2,609 | -2,690 | |
Interest | 0 | 0 | 18 | 551 | 574 | 224 | 388 | 541 | 408 | 268 | 388 | 472 | 728 |
Depreciation | 76 | 86 | 102 | 661 | 464 | 422 | 487 | 553 | 562 | 1,236 | 1,350 | 1,601 | 1,620 |
Profit before tax | 1,726 | 663 | -2,801 | -1,559 | -1,082 | -17 | 280 | 719 | 3,253 | 856 | 307 | 1,741 | 1,018 |
Tax % | 2% | 22% | -1% | 5% | -0% | -36% | -9% | -14% | 1% | 2% | 133% | 3% | |
1,697 | 517 | -2,829 | -1,474 | -1,088 | -23 | 306 | 817 | 3,211 | 842 | -100 | 1,691 | 970 | |
EPS in Rs | 8.20 | 2.49 | -13.66 | -7.12 | -4.52 | -0.10 | 1.27 | 3.40 | 13.38 | 3.51 | -0.42 | 7.05 | 4.05 |
Dividend Payout % | 26% | 50% | -11% | -42% | -22% | -3,677% | 157% | 81% | 30% | 214% | -2,400% | 163% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | 18% |
3 Years: | 18% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 25% |
3 Years: | 4% |
TTM: | 59% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 28% |
3 Years: | 39% |
1 Year: | 63% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 6% |
3 Years: | 4% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 104 | 104 | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Reserves | 7,775 | 7,685 | 7,201 | 22,579 | 21,650 | 20,773 | 22,083 | 22,604 | 24,156 | 26,699 | 24,348 | 23,508 | 23,808 |
40 | 43 | 2,409 | 6,811 | 5,829 | 6,047 | 6,884 | 6,437 | 6,406 | 7,358 | 5,074 | 7,791 | 10,746 | |
1,213 | 1,414 | 4,548 | 7,849 | 6,547 | 6,810 | 7,585 | 8,434 | 7,608 | 9,438 | 11,103 | 9,448 | 6,439 | |
Total Liabilities | 9,131 | 9,246 | 14,364 | 37,446 | 34,266 | 33,869 | 36,792 | 37,714 | 38,410 | 43,735 | 40,765 | 40,987 | 41,233 |
977 | 1,136 | 1,267 | 3,185 | 3,575 | 4,039 | 4,645 | 4,978 | 5,229 | 9,669 | 9,713 | 8,712 | 8,555 | |
CWIP | 249 | 348 | 480 | 1,091 | 768 | 1,100 | 988 | 643 | 597 | 1,090 | 829 | 853 | 304 |
Investments | 4,438 | 4,318 | 7,016 | 25,876 | 22,372 | 19,333 | 18,355 | 17,904 | 17,362 | 15,537 | 15,549 | 12,616 | 12,663 |
3,467 | 3,445 | 5,601 | 7,294 | 7,552 | 9,397 | 12,804 | 14,189 | 15,223 | 17,438 | 14,675 | 18,807 | 19,710 | |
Total Assets | 9,131 | 9,246 | 14,364 | 37,446 | 34,266 | 33,869 | 36,792 | 37,714 | 38,410 | 43,735 | 40,765 | 40,987 | 41,233 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,339 | 106 | -2,405 | 149 | -1,254 | -1,621 | -1,171 | 1,242 | 1,306 | -417 | 7,636 | 507 | |
-771 | 456 | 517 | 2,642 | 3,640 | 2,381 | 1,394 | 431 | 1,483 | 1,452 | -2,697 | -686 | |
-420 | -509 | 1,742 | -2,674 | -2,368 | -753 | -272 | -1,469 | -2,871 | -1,000 | -4,871 | 169 | |
Net Cash Flow | 148 | 53 | -145 | 117 | 17 | 7 | -50 | 205 | -82 | 36 | 68 | -9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65 | 111 | 126 | 82 | 94 | 129 | 214 | 178 | 180 | 170 | 99 | 125 |
Inventory Days | 221 | 354 | 315 | 227 | 260 | 256 | 218 | 277 | 210 | 245 | 220 | 240 |
Days Payable | 138 | 148 | 130 | 164 | 216 | 229 | 262 | 214 | 170 | 288 | 175 | 188 |
Cash Conversion Cycle | 148 | 317 | 311 | 146 | 138 | 155 | 170 | 242 | 220 | 127 | 144 | 177 |
Working Capital Days | 75 | 210 | 370 | -85 | 9 | -35 | 83 | 62 | 122 | 110 | -26 | 131 |
ROCE % | 25% | 8% | 0% | -6% | -3% | -0% | 5% | 8% | 11% | 4% | 8% | 17% |
Documents
Announcements
- Response To Query On Volume Movement 20h
-
Clarification sought from Sun Pharmaceutical Industries Ltd
23h - Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on March 28, 2024, with reference to Movement in Volume.
- Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Regulatory Orders 1d
- Closure of Trading Window 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 23 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Mar 2024TranscriptNotesPPT
-
Feb 2024TranscriptPPT
-
Jan 2024TranscriptNotesPPT
-
Nov 2023TranscriptPPT
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
May 2023TranscriptPPTREC
-
Apr 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
Product Offerings
The company produces a comprehensive and diverse portfolio of generic and specialty medicines targeting wide spectrum of chronic and acute treatments. Its product portfolio includes generics, branded generics, specialty, difficult-to-make technology intensive products, anti-retrovirals, APIs and intermediates.[1] It offers medicines in all form of dosages i.e. injectables, sprays, ointments, creams, liquids, tablets and capsules.[2]